Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.
about
Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknownHSV-2: in pursuit of a vaccineOral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patientsImmune modulation during latent herpesvirus infectionA comparison of herpes simplex virus type 1 and varicella-zoster virus latency and reactivationOcular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated?The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccineHSV-2-driven increase in the expression of α4β7 correlates with increased susceptibility to vaginal SHIV(SF162P3) infectionThe scarlet HHerpes simplex virus-2 transmission probability estimates based on quantity of viral sheddingPsychological distress, emotional stability, and emotion regulation moderate dynamics of herpes simplex virus type 2 recurrence.Herpes genitalis and the philosopher's stance.Virologic and immunologic evidence of multifocal genital herpes simplex virus 2 infection.HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions.Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.Prevention and management of neonatal herpes simplex virus infections.Diagnosis of genital herpes simplex virus infection in the clinical laboratoryFrequent genital HSV-2 shedding among women during labor in Soweto, South AfricaAsymptomatic HLA-A*02:01-restricted epitopes from herpes simplex virus glycoprotein B preferentially recall polyfunctional CD8+ T cells from seropositive asymptomatic individuals and protect HLA transgenic mice against ocular herpes.The murine intravaginal HSV-2 challenge model for investigation of DNA vaccines.Enrichment of herpes simplex virus type 2 (HSV-2) reactive mucosal T cells in the human female genital tract.Current status and prospects for development of an HSV vaccineBlocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.What is new from the Canadian Paediatric Society Committee on Infectious Diseases and Immunization?Prophylactic, therapeutic and neutralizing effects of zinc oxide tetrapod structures against herpes simplex virus type-2 infection.HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression.Short communication: a repeated simian human immunodeficiency virus reverse transcriptase/herpes simplex virus type 2 cochallenge macaque model for the evaluation of microbicidesA single intramuscular vaccination of mice with the HSV-1 VC2 virus with mutations in the glycoprotein K and the membrane protein UL20 confers full protection against lethal intravaginal challenge with virulent HSV-1 and HSV-2 strains.Coping strategies and behavioural changes following a genital herpes diagnosis among an urban sample of underserved Midwestern womenAn HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs.Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humansSerological Profile of HSV-2 in STD Patients: Evaluation of Diagnostic Utility of HSV-2 IgM and IgG DetectionThe impact of brief messages on HSV-2 screening uptake among female defendants in a court setting: a randomized controlled trial utilizing prospect theory.Sexual HIV/HSV-2 risk among drug users in New York City: an HIV testing and counseling intervention.The effects of daily distress and personality on genital HSV shedding and lesions in a randomized, double-blind, placebo-controlled, crossover trial of acyclovir in HSV-2 seropositive womenFunctional fluorescent protein insertions in herpes simplex virus gB report on gB conformation before and after execution of membrane fusion.The known unknowns of HPV natural history.Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individualsAntibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2.A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens
P2860
Q21296712-8211BEBD-C535-46FC-8755-BAE8E5E43503Q22306291-5D934448-F537-4C90-949F-F08325258EEAQ24194490-3C3831CB-2664-41EF-A6BD-F029F3FDA65CQ24624044-634CC9A6-7989-48B0-ABA8-0AECF33982E0Q26996418-B0364EE3-8625-46F1-9697-B25E1343CB1EQ27021069-848D7843-C34C-4A19-A7EF-8CC965763FC8Q27021292-3E9751F9-7070-4AF5-AEF8-21055CB4DD5BQ27322178-55F07B14-9A09-4F33-AEA0-3120A0065421Q28114465-B5CF05FE-FC4C-4B72-AA3E-B4F94210A31CQ28236882-4387A2C3-E8FE-4723-B030-CDFBDEFDA04CQ30303142-D5EC16BD-244B-4219-886C-E31CF514F4E9Q30357939-D1693F69-DF1E-4D1C-A0D1-EBC31E1EDD71Q30576590-2B9BBA5D-92F7-483D-820A-75DC8FF41103Q30830481-48173863-F1ED-4C08-A96D-D530F48E1CA8Q30884457-E25E5FAC-D4B1-43D9-8801-D67AB3CC923DQ33640117-28649FA1-02D0-4C34-B881-ADBFC269D425Q33655295-84B624D1-8764-4529-8237-2A2A04A661BFQ33745846-7A52ACC6-CAB5-4310-A561-080A0A697BB1Q33755236-4219F97E-EA75-49FC-9DDA-EA3555330396Q33856067-209EDE70-375C-479C-AE84-5897B8B6744CQ33870372-704C173B-9989-43A8-BF4B-CC88B005858AQ33931016-A6DAAAC9-7755-4D6E-8F7F-F223747EFE2AQ34057952-F3DC4862-A849-455B-B0E9-40C21DA3651BQ34238518-FEE151F2-2242-4977-80D2-FB40013ACAEFQ34304758-9C1665A4-7833-4C14-B8EA-43A8ACDF0DE8Q34333815-44BBAB06-419F-4A6A-BD71-4369CF28A60BQ34399737-B29A1E3F-3029-4530-BF4F-474A65233243Q34414463-89448C0A-D894-43A0-8639-567098D33DAAQ34467969-0FCAEEAA-BCBF-4374-A3B4-10F157E58298Q34549656-9A04FEFC-5D7D-44CC-B798-149750DF1B59Q34593833-7F1ACF7B-D848-4F0F-AEE6-4E786EEFDF9EQ35046311-76E4A1E2-ADC6-4D38-A8D6-9A0B67A1B973Q35168121-418751E1-5D52-4A0F-B308-EDDEA508A6C3Q35199192-A2FE8622-F0C2-4F2D-8D8B-F3469C9431EBQ35218951-B9AD5620-8219-49D4-8755-C771A97211F9Q35261990-0370AE54-12BB-4B0E-BCA5-2F9CD5624570Q35578583-CBD5812D-DBE9-4991-B61C-0E32152CE8B3Q35868029-48655AF7-D709-40A4-8E76-1538C90D4E98Q35869527-2696FE94-179E-4D34-A15E-1EA82F8F23FCQ35914367-5A8A0387-C0B2-4875-A069-48C71FF4B493
P2860
Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Genital shedding of herpes sim ...... persons with HSV-2 infection.
@ast
Genital shedding of herpes sim ...... persons with HSV-2 infection.
@en
type
label
Genital shedding of herpes sim ...... persons with HSV-2 infection.
@ast
Genital shedding of herpes sim ...... persons with HSV-2 infection.
@en
prefLabel
Genital shedding of herpes sim ...... persons with HSV-2 infection.
@ast
Genital shedding of herpes sim ...... persons with HSV-2 infection.
@en
P2093
P2860
P50
P356
P1476
Genital shedding of herpes sim ...... persons with HSV-2 infection.
@en
P2093
Amalia Magaret
Elizabeth Tronstein
Stacy Selke
Terri Warren
P2860
P304
P356
10.1001/JAMA.2011.420
P407
P577
2011-04-01T00:00:00Z